159 related articles for article (PubMed ID: 33226554)
1. Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma.
Barıs IC; Hacıoglu S; Turk NS; Cetın GO; Zencır S; Bagcı G; Caner V
Clin Transl Oncol; 2021 Jun; 23(6):1152-1166. PubMed ID: 33226554
[TBL] [Abstract][Full Text] [Related]
2. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
4. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
5. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
6. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
[TBL] [Abstract][Full Text] [Related]
7. The miRNA content of circulating exosomes in DLBCL patients and in vitro influence of DLBCL-derived exosomes on miRNA expression of healthy B-cells from peripheral blood.
Caner V; Cetin GO; Hacioglu S; Baris IC; Tepeli E; Turk NS; Bagci G; Yararbas K; Cagliyan G
Cancer Biomark; 2021; 32(4):519-529. PubMed ID: 34275894
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2.
Xu H; Zhao G; Zhang Y; Jiang H; Wang W; Zhao D; Hong J; Yu H; Qi L
Stem Cell Res Ther; 2019 Dec; 10(1):381. PubMed ID: 31842978
[TBL] [Abstract][Full Text] [Related]
9. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F
Blood; 2017 Apr; 129(17):2420-2428. PubMed ID: 28167662
[TBL] [Abstract][Full Text] [Related]
10. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
11. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
12. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
[TBL] [Abstract][Full Text] [Related]
16. Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.
Brown RE; Zhang S; Wang XI
Ann Clin Lab Sci; 2022 Jan; 52(1):27-32. PubMed ID: 35181615
[TBL] [Abstract][Full Text] [Related]
17. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
Duncan VE; Ping Z; Varambally S; Peker D
Leuk Lymphoma; 2017 Jan; 58(1):179-184. PubMed ID: 27184221
[TBL] [Abstract][Full Text] [Related]
18. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of genome‑wide gene expression and DNA methylation microarray of diffuse large B‑cell lymphoma with TET mutations.
Liu P; Jiang W; Zhao J; Zhang H
Mol Med Rep; 2017 Oct; 16(4):3777-3782. PubMed ID: 28731140
[TBL] [Abstract][Full Text] [Related]
20. [Plasma DNA methylation of shp1 in patients with diffuse large B cell lymphoma].
Chen X; Fu R; Wang Y; Song W; Ruan E; Qu W; Wang H; Wang G; Song J; Wang X; Wu Y; Xing L; Liu H; Li L; Guan J; Shao Z
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(14):1071-5. PubMed ID: 24851890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
